

BWC Antibigram 2024																
GRAM NEGATIVE		ANTIBIOTICS														
1/1/2024-12/31/2024	Number tested	Amoxicillin/Clavulanic Acid	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin ^(a)	Levofloxacin	Meropenem	Nitrofurantoin	Piperacillin/Tazobactam	Tetracycline	Tobramycin ^(a)	Trimeth/Sulfa
	PERCENT SUSCEPTIBLE															
	Enterobacter cloacae complex	50	•		•	96	•	94		98	98	96	22	•		96
	Escherichia coli	645	83		82	92	88	68	#	93	69	100	96	96		77
	Escherichia coli (ED only)	160	88		86	93	91	72	#	96	74	99	96	95		78
	Klebsiella pneumoniae	181	95		90	94	92	84	#	99	84	99	25	97		89
	Proteus mirabilis	82	89		89	98	95	87	#	96	87	99	0	100		83
Pseudomonas aeruginosa	127				91			83			79	95		92		

GRAM POSITIVE		ANTIBIOTICS											
1/1/2024-12/31/2024	Number tested	Ampicillin	Clindamycin	Erythromycin	Gentamycin (High-Level)	Linezolid	Nitrofurantoin	Oxacillin	Streptomycin (High-Level)	Tetracycline	Trimeth/Sulfa	Vancomycin	
	PERCENT SUSCEPTIBLE												
	Organism												
	Enterococcus faecalis	105	100			83	100	100		91	26		96
	Staphylococcus aureus, ALL	152		75	51		100		71		88	91	100
	MRSA only	45		69	12		100		0		77	77	100
	MSSA only	107		75	65		100		100		92	96	100
Staphylococcus epidermidis	68		72	43		100		50		78	66	100	

85-100% Susceptible

60-84% Susceptible

<60% Susceptible

#

Not routinely tested. Historical data suggests frequent susceptibility; confirm with microbiology when relevant

•

Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated

Shaded boxes indicate organism/antimicrobial combines not tested routinely

(a) Aminoglycoside breakpoints were lowered in 2023 for Enterobacterales and Pseudomonas aeruginosa. Gentamicin should no longer be used for the treatment of Pseudomonas aeruginosa infections.